Aurora A/AIK antibody | knockout validation | Cell Signaling 4718

This is a knockout-validated antibody summary, based on the publication "Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Aurora A/AIK antibody | knockout validation | Cell Signaling 4718 figure 1
Figure 1. Western blot for AURKA expression in clonal knockout cells derived from PC9-Cas9-RIT1M90I cells. Vinculin was used as a loading control. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: Aurora A/AIK

Catalog number: 4718

Summary: Rabbit monoclonal antibody against a synthetic peptide corresponding to the amino terminus of human Aurora A/AIK. Reacts with human and monkey. Suitable for western blot and immunofluorescence (immunocytochemistry).

Validation Method

Western blot

Sample

Control and AURKA-KO PC9 cells.

Blocking agent

Tris Buffered Saline (TBS) with 1% Casein (BioRad) for 1h at room temperature.

Primary incubation

1:500 dilution in blocking buffer overnight at 4°C.

Secondary incubation

StarBright (BioRad) or IRDye (LiCOR) secondary antibodies.

Detection

ChemiDoc MP Imaging System (BioRad).

References
  1. Vichas A, Riley A, Nkinsi N, Kamlapurkar S, Parrish P, Lo A, et al. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nat Commun. 2021;12:4789 pubmed publisher